neupro

vimpat
Name

NEUPRO® (Rotigotine)

 

NEUPRO® (Rotigotine Transdermal System) is a dopamine agonist that works by helping to restore the balance of dopamine in the brain. NEUPRO®  is indicated for the treatment of the signs and symptoms of early-stage idiopathic Parkinson’s disease as monotherapy (i.e. without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or “on-off” fluctuations).

Description NEUPRO® is a non-ergolinic dopamine agonist transdermal patch agonist that works by helping to restore the balance of dopamine in the brain
Indication NEUPRO®  is indicated for the treatment of the signs and symptoms of early-stage idiopathic Parkinson’s disease as monotherapy (i.e. without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or “on-off” fluctuations).
Strengths Transdermal System: 2 mg, 4 mg, 6 mg and 8 mg rotigotine per 24 hours
Regulatory Status

EMA approved in February 2006

FDA approved in May 2007

Registered in Bahrain, Kuwait, Oman, UAE, Lebanon, Jordan (4 mg/24 h and 6 mg/24 h) and KSA

Business Partner UCB

 

vimpat